Format

Send to

Choose Destination
Eur J Clin Pharmacol. 2006 Dec;62(12):1021-31. Epub 2006 Oct 20.

The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.

Author information

1
Shoklo Malaria Research Unit, P.O. Box 46, Mae Sot, Tak, Thailand.

Erratum in

  • Eur J Clin Pharmacol. 2009 Aug;65(8):847.

Abstract

OBJECTIVE:

To determine the pharmacokinetic properties of artemether and lumefantrine (AL) in pregnant women with recrudescent uncomplicated multi-drug resistant falciparum malaria.

METHODS:

Pregnant women who had recurrence of parasitaemia following 7 days supervised quinine treatment were treated with AL. Serial blood samples were taken over a 7-day period, and pharmacokinetic parameters were estimated. For lumefantrine, these data were compared in a population pharmacokinetic model with data from non-pregnant, mainly male adults with acute malaria.

RESULTS:

The pregnant women (five in the second trimester and eight in the third trimester) had lower concentrations of artemether, dihydroartemisinin and lumefantrine, and the elimination of lumefantrine in pregnant women was more rapid than reported previously in non-pregnant adults.

CONCLUSION:

Pregnancy is associated with reduced plasma concentrations of both artemether and lumefantrine. This is likely to be of therapeutic significance as plasma concentrations of lumefantrine, after elimination of artemether, are an important determinant of cure. Further studies are needed to determine the optimum dose regimen of artemether-lumefantrine in pregnancy.

PMID:
17053895
DOI:
10.1007/s00228-006-0199-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center